Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences High-Content and Phenotypic Screening Europe 2018
Conferences  \  High-Content and Phenotypic Screening Europe 2018  \  Agenda  \  Simon Hufton
RegisterLogin

Simon Hufton's Biography


Simon Hufton, Section Head Molecular Immunology, National Institute for Biological Standard and Control (NIBSC)

Dr Simon E. Hufton has over 20-years’ experience in the therapeutic monoclonal antibody field gained as Director Research for Dyax Corp and Wyeth. He joined NIBSC in 2009 and is currently Head of Molecular Immunology within the Biotherapeutics Division. He has authored over 40 publications and patents covering various aspects of monoclonal antibody research and development including biomolecular display technologies and single domain antibodies. He is a biochemist by training and received his undergraduate degree from The University of Manchester, UK and his PhD at Nottingham University, UK. His research interests include immunotherapy and antibody engineering related to efficacy, quality and safety of biological medicines.

Simon Hufton Image

Nanobodies Against Influenza and Their Applications in Preparing For Future Pandemics

Friday, 25 May 2018 at 13:30

Add to Calendar ▼2018-05-25 13:30:002018-05-25 14:30:00Europe/LondonNanobodies Against Influenza and Their Applications in Preparing For Future PandemicsHigh-Content and Phenotypic Screening Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

Both seasonal and pandemic influenza continue to represent a formidable public health challenge. The constant evolution of new strains means the rapid availability of highly specific neutralising monoclonal antibodies are of considerable interest. Nanobodies are emerging as next generation antibodies with a number of well documented advantages which make them highly amenable to applications in the infectious disease area. This presentation will describe the isolation and characterization of nanobodies specific for key influenza subtypes including ‘swine flu’ A(H1N1), highly pathogenic avian influenza A(H5N1), highly pathogenic avian influenza A(H7N9), A(H3N2) and B lineage influenza viruses. The use of yeast display for mapping their epitopes on hemagglutinin will also be presented as will their potential applications in preparing for future influenza pandemics.

Add to Calendar ▼2018-05-24 00:00:002018-05-25 00:00:00Europe/LondonHigh-Content and Phenotypic Screening Europe 2018High-Content and Phenotypic Screening Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors
Related Conferences
Innovations in Flow Cytometry & Extracellular Vesicles 2024
Location: Laguna Hills, California
Date: 18/11/2024 - 20/11/2024


Organoids and Spheroids Europe 2024
Location: Rotterdam, The Netherlands
Date: 24/06/2024 - 25/06/2024


Lab-on-a-Chip, Microfluidics, & Organ-on-a-Chip Asia 2024
Location: Tokyo, Japan
Date: 07/11/2024 - 08/11/2024